/* SLIDE GALLERY FOR HOME PAGE */ /* SLIDE GALLERY FOR ABOUT CARDICA */


PAS-Port® System

C-Port System

PAS-Port® Proximal Anastomosis System
(PAS-Port system)


Our PAS-Port system is a fully-automated device used to perform an anastomosis between a saphenous vein and the aorta during either on- or off-pump CABG surgery. The PAS-Port system has been used in Japan and Europe since 2004, and received
510(k) clearance in the United States in 2008.

Brochure

PAS-Port® Product Brochure

The PAS-Port system is designed to:

"Eliminate aortic clamping and manipulation."

  • Eliminate clamping, which may greatly reduce the risk of particle release and ensuing neurocognitive events
  • Allow the surgeon to load the bypass graft and rapidly complete the anastomosis, typically in approximately one minute
  • Provide one-turn aortotomy and anastomosis
  • Reduce time required for anastomosis
  • Produce consistent, reproducible anastomoses, largely independent of surgical technique and skill set
  • Ensure secure graft attachment allowing for variable take-off angles
  • Leave no metal within the graft lumen
  • Be loaded into the system without damaging endothelial cells while maximizing the orifice, especially important in small grafts
  • Allow mechanically-governed repeatability and reduced procedural complexity

Pull Through
The bypass vessel graft is pulled through the PAS-Port system in preparation for deployment.
Eversion
The graft vessel is everted in preparation for deployment.
Poke Through
The vessel is prepared and ready to attach to the aorta.

PAS-Port System Met All Endpoints in Pivotal Trial

Cardica conducted a 220-patient, prospective, pivotal, randomized trial of the PAS-Port® system at 12 sites in the United States and Europe. The trial compared venous bypass grafts to the aorta made using the PAS-Port system versus those made using conventional hand-sewn sutures. Results showed that the study met its primary endpoint of non-inferiority to hand-sewn anastomoses, as well as all other primary and secondary endpoints.

The results of the EPIC trial have been published in the July 2009 issue of The Journal of Thoracic & Cardiovascular Surgery. To view this study, click here.

For more information about Cardica products, please contact sales.




Cardica, Inc. is now Dextera Surgical Inc. Dextera Surgical Inc. will continue to manufacture & distribute the Cardica-branded products.
> Read More
Dextera Surgicals stapling technology is designed to minimize operating time and to enable minimally-invasive and robot-assisted surgeries.
> Read More
Receive all the latest updates about Dextera Surgical
Share this website with your friends.